The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
A Once-Daily, Oral, Direct Factor Xa Inhibitor, Rivaroxaban (BAY 59-7939), for Thromboprophylaxis After Total Hip Replacement
Open accessAbstract
Background— Rivaroxaban (BAY 59-7939)—an oral, direct Factor Xa inhibitor—could be an alternative to heparins and warfarin for the prevention and treatment of thromboembolic disorders. Methods and Results— This randomized, double-blind, double-dummy, active-comparator–controlled, multinational, dose-ranging study assessed the efficacy and safety of once-daily rivaroxaban relative to enoxaparin for prevention of venous thromboembolism in patients undergoing elective total hip replacement. Patients (n=873) were randomized to once-daily oral rivaroxaban doses of 5, 10, 20, 30, or 40 mg (initiated 6 to 8 hours after surgery) or a once-daily subcutaneous enoxaparin dose of 40 mg (given the evening before and ≥6 hours after surgery). Study drugs were continued for an additional 5 to 9 days; mandatory bilateral venography was performed the following day. The primary end point (composite of any deep vein thrombosis, objectively confirmed pulmonary embolism, and all-cause mortality) was observed in 14.9%, 10.6%, 8.5%, 13.5%, 6.4%, and 25.2% of patients receiving 5, 10, 20, 30, and 40 mg rivaroxaban, and 40 mg enoxaparin, respectively (n=618, per-protocol population). No significant dose–response relationship was found for efficacy ( P =0.0852). Major postoperative bleeding was observed in 2.3%, 0.7%, 4.3%, 4.9%, 5.1%, and 1.9% of patients receiving 5, 10, 20, 30, and 40 mg rivaroxaban, and 40 mg enoxaparin, respectively (n=845, safety population), representing a significant dose–response relationship ( P =0.0391). Conclusions— Rivaroxaban showed efficacy and safety similar to enoxaparin for thromboprophylaxis after total hip replacement, with the convenience of once-daily oral dosing and without the need for coagulation monitoring. When both efficacy and safety are considered, these results suggest that 10 mg rivaroxaban once daily should be investigated in phase III studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of Venous Thromboembolism
Geerts, W. H., Pineo, G. F., Heit, J. A., Bergqvist, D., Lassen, M. R., Colwell, C. W., & Ray, J. G. (2004) · Chest · doi:10.1378/chest.126.3_suppl.338s · Cited by 5,895
Prevention of Venous Thromboembolism
Geerts, W. H., Heit, J. A., Clagett, G. P., Pineo, G. F., Colwell, C. W., Anderson, F. A., & Wheeler, H. B. (2001) · Chest · doi:10.1378/chest.119.1_suppl.132s · Cited by 4,373
Roentgen Diagnosis of Venous Thrombosis in the Leg
Rabinov, K. (1972) · Archives of Surgery · doi:10.1001/archsurg.1972.04180020014004 · Cited by 740
KUBITZA, D., BECKA, M., VOITH, B., ZUEHLSDORF, M., & WENSING, G. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.06.011 · Cited by 649
Kubitza, D., Becka, M., Wensing, G., Voith, B., & Zuehlsdorf, M. (2005) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-005-0043-5 · Cited by 640
Turpie, A. G., Bauer, K. A., Eriksson, B. I., & Lassen, M. R. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08648-8 · Cited by 537
Self-citationCommittee for Proprietary Medicinal Products (CPMP)
Nahler, G. (2009) · Dictionary of Pharmaceutical Medicine · doi:10.1007/978-3-211-89836-9_243 · Cited by 441
TURPIE, A. G. G., FISHER, W. D., BAUER, K. A., KWONG, L. M., IRWIN, M. W., KÄLEBO, P., MISSELWITZ, F., & GENT, M. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01602.x · Cited by 302
Self-citationERIKSSON, B. I., BORRIS, L., DAHL, O. E., HAAS, S., HUISMAN, M. V., KAKKAR, A. K., MISSELWITZ, F., & KÄLEBO, P. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01657.x · Cited by 302
Self-citationAgnelli, G., Cohen, A., Dahl, O., Mouret, P., Rosencher, N., Eskilson, C., Nylander, I., Frison, L., ögren, M., Eriksson, B., et al. (2003) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613445 · Cited by 252
Self-citationEriksson, B. I., Kälebo, P., Bergqvisty, D., Dahl, O. E., Lindbratt, S., Bylock, A., Frison, L., Eriksson, U., Welin, L., & Gustafsson, D. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11469-3 · Cited by 248
Self-citationEriksson, B. I., Agnelli, G., Cohen, A. T., Dahl, O. E., Lassen, M. R., Mouret, P., Rosencher, N., Kälebo, P., Panfilov, S., Eskilson, C., et al. (2003) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2003.00494.x · Cited by 199
Self-citationPharmacokinetics of BAY 59-7939 – an oral, direct Factor Xa inhibitor – in rats and dogs
Weinz, C., Buetehorn, U., Daehler, H.-P., Kohlsdorfer, C., Pleiß, U., Sandmann, S., Schlemmer, K., Schwarz, T., & Steinke, W. (2005) · Xenobiotica · doi:10.1080/00498250500250493 · Cited by 100
Kälebo, P., Ekman, S., Lindbratt, S., Eriksson, B. I., Pauli, U., Zachrisson, B. E., & Close, P. (1996) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1650682 · Cited by 38
Self-citationKubitza, D., Becka, M., Wensing, G., Voith, B., & Zuehlsdorf, M. (2003) · Blood · Cited by 21
Cited by
Kahn (2012) · doi:10.1378/chest.11-2296 · Cited by 2,693
Prevention of VTE in Orthopedic Surgery Patients
Falck-Ytter, Y., Francis, C. W., Johanson, N. A., Curley, C., Dahl, O. E., Schulman, S., Ortel, T. L., Pauker, S. G., & Colwell, C. W. (2012) · Chest · doi:10.1378/chest.11-2404 · Cited by 1,930
Self-citationHorlocker, T. T., Wedel, D. J., Rowlingson, J. C., Enneking, F. K., Kopp, S. L., Benzon, H. T., Brown, D. L., Heit, J. A., Mulroy, M. F., Rosenquist, R. W., et al. (2010) · Regional Anesthesia and Pain Medicine · doi:10.1097/aap.0b013e3181c15c70 · Cited by 1,501
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
Eriksson, B. I., Borris, L. C., Friedman, R. J., Haas, S., Huisman, M. V., Kakkar, A. K., Bandel, T. J., Beckmann, H., Muehlhofer, E., Misselwitz, F., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800374 · Cited by 1,433
Self-citationRivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty
Lassen, M. R., Ageno, W., Borris, L. C., Lieberman, J. R., Rosencher, N., Bandel, T. J., Misselwitz, F., & Turpie, A. G. G. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa076016 · Cited by 1,295
Self-citation
Metadata
- Authors
- Eriksson, B. I., Borris, L. C., Dahl, O. E., Haas, S., Huisman, M. V., Kakkar, A. K., Muehlhofer, E., Dierig, C., Misselwitz, F., & Kälebo, P.
- Venue
- Circulation
- Published
- 2006-11-28
- Volume
- 114
- Issue
- 22
- Pages
- 2374-2381
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2115513773
- Cited by
- 335
- References
- 15
- FWCI
- 21.02
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.